UNSPSC 51422341: Dexamethasone pivalate

This classification denotes a therapeutic glucocorticoid and antiemetic agent C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K182597N9C, chemically known as pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-, but more generally known as dexamethasone pivalate, which bears US NIH Compound Identifier 63040. European Medicines Agency schedules Dexamethasone pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01613MIG.

UNSPSC 51422341 Dexamethasone pivalate is a Commodity code that appears in state and local procurement records with minimal recent activity directly aligned to the code's pharmaceutical scope. The single recent opportunity in the dataset is Seminole County, Florida's IFB60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, which solicits Naloxone and Safe Drug Deactivation Systems — a public health consumable unrelated to dexamethasone pivalate. This mismatch suggests either a coding error in the source data or that the county's procurement system tagged the opportunity with an incorrect UNSPSC classifier. The opportunity itself calls for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to Seminole County Community Health Building in Sanford, Florida, under an IFB contract with an initial two-year term and one-year renewal option; vendors must include all shipping and delivery costs in their bids, maintain workers' compensation and commercial general liability insurance, and comply with E-Verify requirements and potential FEMA-related federal compliance obligations.

The code shows no other recent state or local solicitations in the dataset. Because the single posted opportunity under this code does not align with dexamethasone pivalate procurement, there is no reliable geographic concentration, repeat-buyer pattern, or representative recent opportunity to characterize for business development purposes. Firms pursuing pharmaceutical products under UNSPSC codes should verify classifier accuracy in procurement notices before responding, as miscoding may direct buyers and vendors to the wrong product lines.